Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria M Balwani, E Sardh, P Ventura, PA Peiró, DC Rees, U Stölzel, DM Bissell, ... New England journal of medicine 382 (24), 2289-2301, 2020 | 493 | 2020 |
EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks L Gouya, P Ventura, M Balwani, DM Bissell, DC Rees, U Stölzel, ... Hepatology 71 (5), 1546-1558, 2020 | 150 | 2020 |
Increasing patient involvement in drug development MM Lowe, DA Blaser, L Cone, S Arcona, J Ko, R Sasane, P Wicks Value in Health 19 (6), 869-878, 2016 | 107 | 2016 |
Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year KM Johnson, H Zhou, F Lin, JJ Ko, V Herrera Journal of Managed Care & Specialty Pharmacy 23 (8), 844-852, 2017 | 91 | 2017 |
The effect of formulary restrictions on patient and payer outcomes: a systematic literature review Y Park, S Raza, A George, R Agrawal, J Ko Journal of managed care & specialty pharmacy 23 (8), 893-901, 2017 | 74 | 2017 |
Outcomes-based contracting experience: research findings from US and European stakeholders T Nazareth, JJ Ko, R Sasane, C Frois, S Carpenter, S Demean, ... Journal of managed care & specialty pharmacy 23 (10), 1018-1026, 2017 | 61 | 2017 |
Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study P Ventura, HL Bonkovsky, L Gouya, P Aguilera‐Peiró, ... Liver International 42 (1), 161-172, 2022 | 59 | 2022 |
Detecting rare diseases in electronic health records using machine learning and knowledge engineering: case study of acute hepatic porphyria AM Cohen, S Chamberlin, T Deloughery, M Nguyen, S Bedrick, ... Plos one 15 (7), e0235574, 2020 | 44 | 2020 |
The impact of disease-modifying therapy access barriers on people with multiple sclerosis: mixed-methods study KF Simacek, JJ Ko, D Moreton, S Varga, K Johnson, BJ Katic Journal of medical Internet research 20 (10), e11168, 2018 | 43 | 2018 |
Analysis of glycemic control of a pharmacist-led medication management program in patients with type 2 diabetes JJ Ko, J Lu, K Rascati, EM Stock, J Juan, K Suh, Y Kim, PA Tabor, ... Journal of managed care & specialty pharmacy 22 (1), 32-37, 2016 | 33 | 2016 |
The impact of price reductions after loss of exclusivity in a cost-effectiveness analysis: fingolimod versus interferon beta-1a for the treatment of relapsing-remitting … LH Hua, CM Hersh, P Morten, J Kusel, F Lin, J Cave, S Varga, V Herrera, ... Journal of managed care & specialty pharmacy 25 (4), 490-498, 2019 | 19 | 2019 |
Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective … T Nazareth, HS Friedman, P Navaratnam, DA Herriott, JJ Ko, P Barr, ... BMC neurology 16, 1-10, 2016 | 16 | 2016 |
Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study L Gill, S Burrell, J Chamberlayne, S Lombardelli, J Mora, N Mason, ... Orphanet Journal of Rare Diseases 16, 1-14, 2021 | 12 | 2021 |
Quantifying the impact of symptomatic acute hepatic porphyria on well‐being via patient‐reported outcomes: Results from the Porphyria Worldwide Patient Experience Research … A Dickey, K Wheeden, D Lyon, S Burrell, S Hegarty, R Falchetto, ... JIMD reports 64 (1), 104-113, 2023 | 11 | 2023 |
Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing–remitting multiple sclerosis patients J Nicholas, JJ Ko, Y Park, P Navaratnam, HS Friedman, FR Ernst, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 3 (1 …, 2017 | 9 | 2017 |
Patient perspective on acute hepatic porphyria with sporadic attacks: a chronic disease with substantial health-related quality of life impacts K Wheeden, D Lyon Howe, S Burrell, L Gill, J Chamberlayne, ER Williams, ... Advances in Therapy 39 (9), 4330-4345, 2022 | 8 | 2022 |
ENVISION, a phase 3 study of safety and efficacy of givosiran, an investigational RNAi therapeutic, in acute hepatic porphyria patients DM Bissell, L Gouya, M Balwani, D Rees, P Stein, U Stolzel, PA Peiro, ... Hepatology 70, 100A-101A, 2019 | 7 | 2019 |
Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the envision open label extension E Sardh, M Balwani, D Rees, P Stein, U Stözel, P Aguilera, DM Bissell, ... Journal of Hepatology 73, S62-S63, 2020 | 6 | 2020 |
Eighteen-month interim analysis of efficacy and safety of givosiran, an RNAi therapeutic for acute hepatic porphyria, in the envision open label extension DJ Kuter, S Keel, CJ Parker, DC Rees, U Stölzel, P Ventura, M Balwani, ... Blood 136, 13, 2020 | 5 | 2020 |
Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: payer and manufacturer experience and outlook T Nazareth, JJ Ko, C Frois, S Carpenter, S Demean, EQ Wu, R Sasane, ... Value in Health 18 (3), A100, 2015 | 5 | 2015 |